Safety and Efficacy of NAFT900 in Children With Tinea Capitis

Merz Pharmaceuticals logo

Merz Pharmaceuticals

Status and phase

Withdrawn
Phase 2

Conditions

Tinea Capitis

Treatments

Drug: Naftifine hydrochloride foam, 3%
Drug: Vehicle

Study type

Interventional

Funder types

Industry

Identifiers

NCT02658292
M902001001

Details and patient eligibility

About

A Double-Blind, Randomized, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of NAFT-900 in Children Aged 6 to \< 13 Years with Tinea Capitis

Full description

This is an 8-week double-blind, randomized, vehicle-controlled, multicenter study of NAFT-900 compared to vehicle in the treatment of tinea capitis in children ≥6 years to <13 years of age. There will be approximately 60 subjects enrolled. Qualifying subjects with clinical evidence of a tinea capitis infection involving ≤ 15% of the scalp, confirmed by positive culture, will be randomized 2:1 to one of the following treatments: NAFT-900 (Naftifine hydrochloride foam, 3%) Vehicle Foam The study will consist of up to 6 visits. Subjects will apply the assigned study product twice daily to the affected area(s) for 4 weeks

Sex

All

Ages

6 to 12 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Subjects with clinical diagnosis of tinea capitis with ≤15% involvement of the scalp.
  2. Subjects with positive KOH microscopy and culture [for dermatophytes].
  3. Male or female subjects ≥6 years and <13 years of age on the date of the Baseline Visit.

Exclusion criteria

  1. Subject with acute inflammatory fungal infection of the scalp (kerion)
  2. Subjects with skin disease on the scalp, or any other condition or prior/present treatment which in the opinion of the investigator would interfere with the study drug's effect or assessments (e.g., psoriasis, seborrheic dermatitis).
  3. Subjects who received immunosuppressant therapy, cytostatic therapy or radiation therapy within 4 weeks prior to the baseline.
  4. Subjects who received systemic corticosteroids and/or systemic antibiotics within 4 weeks prior to study entry (or during study).
  5. Subjects who have used systemic antifungal treatment within 4 weeks prior to the baseline.
  6. Subjects who have used antifungal agents, corticosteroid preparations, ketoconazole, ciclopirox, salicylic acid, terbinafine, amorolfine, butenafine, clotrimazole, econazole, oxiconazole, sertaconazole, sulconazole, luliconazole, fluconazole, benzoic acid, griseofulvin, undecylenic acid, zinc pyrithione or selenium sulfide, or tar containing topical treatments for their scalp within 1 week prior to the baseline visit.
  7. Subjects with a life-threatening condition (ex. autoimmune deficiency syndrome, cancer, unstable angina, or myocardial infarction) within the last 6 months prior to baseline visit.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

0 participants in 2 patient groups, including a placebo group

NAFT900
Active Comparator group
Description:
NAFT900 (Naftifine hydrochloride foam, 3%)
Treatment:
Drug: Naftifine hydrochloride foam, 3%
Vehicle
Placebo Comparator group
Description:
Vehicle Foam
Treatment:
Drug: Vehicle

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems